Pharvaris N.V. Stock Price, News & Analysis

Pharvaris (Nasdaq: PHVS) announced positive results from the RAPIDe-1 Phase 2 clinical study of PHVS416, a novel oral treatment for hereditary angioedema (HAE). Key findings include:

• The primary endpoint was met, showing significant symptom relief.
• All secondary endpoints were achieved, demonstrating rapid onset and efficacy.
• PHVS416 was well tolerated across all dose levels.

Overall, the study indicates PHVS416's potential as an effective on-demand therapy for HAE attacks.

Pharvaris (Nasdaq: PHVS) has announced its participation in the ACAAI Annual Scientific Meeting 2022, taking place from November 10-14, 2022. The company will present two ePosters, highlighting promising pharmacokinetic profiles of its investigational drugs PHVS719 and PHVS416 for hereditary angioedema (HAE). PHVS719 aims for once-daily prophylactic treatment, demonstrating sustained therapeutic levels. Key presentations will showcase pharmacokinetic data and tolerability results, with no severe adverse events reported during early clinical trials.

Pharvaris (Nasdaq: PHVS) presented preclinical and clinical data for its novel oral bradykinin B2 receptor antagonists, PHA121, PHVS416, and PHVS719, at the 2022 HAEi Global Leadership Workshop in Frankfurt, Germany. These treatments target hereditary angioedema (HAE) attacks, with PHVS416 designed for on-demand relief and PHVS719 for daily prophylaxis. Key findings indicate that PHA121 is 25-fold more potent than existing therapies, with promising pharmacokinetics for both formulations, offering rapid and sustained therapeutic effects in HAE management.

Pharvaris (Nasdaq: PHVS) announced the promotion of Annick Deschoolmeester to Chief Human Resources Officer. Ms. Deschoolmeester will manage talent acquisition, employee relations, and diversity initiatives. Her recent contributions are noted as vital for the company's strategic growth. She joined Pharvaris in September 2021, bringing over 25 years of HR experience, previously holding roles at Takeda Pharmaceuticals and other major firms. Pharvaris is focused on developing oral bradykinin-B2-receptor antagonists for treating hereditary angioedema (HAE).

Pharvaris (Nasdaq: PHVS) presented significant data on PHA121 at the Bradykinin Symposium 2022 in Berlin, supporting its development for hereditary angioedema (HAE) treatment. The clinical data demonstrate that PHA121 is 25-fold more potent than icatibant for inhibiting bradykinin interaction. The pharmacokinetics for PHVS416 provide therapeutic exposure within 30 minutes, while PHVS719 offers extended release for daily prophylaxis. Pharvaris aims to offer effective alternatives for HAE treatment through its drug development efforts.

Pharvaris (Nasdaq: PHVS) announced the receipt of formal letters from the FDA regarding a clinical hold on PHA121 studies in the U.S., necessitating additional long-term studies. Top-line data from the global Phase 2 RAPIDe-1 study of PHVS416 for hereditary angioedema (HAE) attacks is expected in 4Q22. As of June 30, 2022, the company reported cash and equivalents of €201 million, down from €209 million at year-end 2021. R&D and G&A expenses rose significantly to €13.7 million and €7.7 million respectively, while the loss for Q2 2022 was €12.6 million, down from €15.2 million a year earlier.

Pharvaris (Nasdaq: PHVS) announced a clinical hold by the FDA on trials for PHA121, a treatment for hereditary angioedema (HAE). The hold is due to the FDA's review of nonclinical data, with a formal letter expected in 30 days. CEO Berndt Modig emphasized the company's commitment to addressing the FDA's concerns and continuing its work on developing new therapies for HAE. This setback raises questions about the progress of their clinical trials for PHA121, PHVS416, and PHVS719, which are currently on hold.

Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on treating hereditary angioedema (HAE), will participate in a fireside chat at the H.C. Wainwright 1st Annual HAE Conference on July 20, 2022, at 1:30 PM EDT. This virtual event aims to discuss Pharvaris' novel oral bradykinin-B2-receptor antagonists. A live webcast will be accessible on their website, with a replay available for 30 days post-event.

Pharvaris targets effective treatment alternatives for HAE, leveraging their deep industry expertise.

Pharvaris (Nasdaq: PHVS), a clinical-stage company, announced a virtual webinar on July 13, 2022, titled Expert Perspectives on HAE: Unmet Needs and Therapeutic Options. The event will address the current landscape of Hereditary Angioedema (HAE), featuring insights from community members and physicians. Key speakers include Anthony J. Castaldo from HAE International, Dr. Marc A. Riedl from UCSD, Berndt Modig, and Dr. Peng Lu from Pharvaris. Registration for the live webcast is available on their website, with an archived replay accessible for 30 days post-event.